MA54958A - Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée - Google Patents

Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée

Info

Publication number
MA54958A
MA54958A MA054958A MA54958A MA54958A MA 54958 A MA54958 A MA 54958A MA 054958 A MA054958 A MA 054958A MA 54958 A MA54958 A MA 54958A MA 54958 A MA54958 A MA 54958A
Authority
MA
Morocco
Prior art keywords
modulation
closed
protein activity
rep protein
end dna
Prior art date
Application number
MA054958A
Other languages
English (en)
Inventor
Robert Michael Kotin
Ara Karl Malakian
Anna Ucher
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA54958A publication Critical patent/MA54958A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054958A 2019-02-15 2020-02-14 Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée MA54958A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962806076P 2019-02-15 2019-02-15

Publications (1)

Publication Number Publication Date
MA54958A true MA54958A (fr) 2021-12-22

Family

ID=72045641

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054958A MA54958A (fr) 2019-02-15 2020-02-14 Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée

Country Status (11)

Country Link
US (1) US20220127625A1 (fr)
EP (1) EP3924491A4 (fr)
JP (2) JP7644014B2 (fr)
KR (1) KR20210127935A (fr)
CN (1) CN113454232B (fr)
AU (1) AU2020221312A1 (fr)
CA (1) CA3129321A1 (fr)
IL (1) IL285415A (fr)
MA (1) MA54958A (fr)
SG (1) SG11202106491VA (fr)
WO (1) WO2020168222A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
JP2022536338A (ja) * 2019-06-10 2022-08-15 ホモロジー・メディシンズ・インコーポレイテッド Ａｒｓａ遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法
WO2022023284A1 (fr) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions de molécules d'adn, leurs procédés de fabrication et leurs procédés d'utilisation
EP4214309A4 (fr) * 2020-09-16 2025-07-16 Generation Bio Co Vecteurs d'adn à extrémité fermée et utilisations associées pour exprimer de la phénylalanine hydroxylase (pah)
WO2022136616A1 (fr) * 2020-12-23 2022-06-30 Vivet Therapeutics Promoteurs inductibles par l'acide biliaire minimal pour thérapie génique
US20240182925A1 (en) * 2021-03-16 2024-06-06 Wisconsin Alumni Research Foundation Insulin gene therapy to treat diabetes
JP2024534123A (ja) * 2021-08-23 2024-09-18 バイオベラティブ セラピューティクス インコーポレイテッド バキュロウイルス発現システム
CN114703203B (zh) * 2022-02-11 2024-08-06 上海渤因生物科技有限公司 杆状病毒载体及其用途
KR102737146B1 (ko) * 2023-07-10 2024-12-09 대한민국 신규 발현 벡터 및 이의 용도
WO2025114932A1 (fr) * 2023-11-30 2025-06-05 Sanofi Purification de molécules d'adn à extrémité fermée
US12509711B1 (en) * 2024-08-09 2025-12-30 Martin Williams System and process for in vivo manufacturing nanostructure-ended double-stranded covalently-closed linear DNA, the resulting molecules and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2596292C (fr) * 1997-03-21 2012-05-22 Enzo Therapeutics, Inc. Vecteurs et vecteurs viraux et lignees de cellules d'encapsidation les propageant
AU7953900A (en) * 1999-10-29 2001-05-14 Takara Shuzo Co., Ltd. Gene transfer method
ES2785223T3 (es) * 2006-06-21 2020-10-06 Uniqure Ip Bv Células de insecto para la producción de vectores de AAV
EP2545165B1 (fr) * 2010-03-11 2020-07-29 uniQure IP B.V. Séquences codant une protéine rep mutée destinées à être utilisées dans la production d'aav
EP2500434A1 (fr) * 2011-03-12 2012-09-19 Association Institut de Myologie Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
EP4450630A3 (fr) * 2014-03-10 2025-01-29 uniQure IP B.V. Vecteurs aav encore améliorés produits dans des cellules d'insectes
SG10201913688TA (en) * 2016-03-03 2020-03-30 Univ Massachusetts Closed-ended linear duplex dna for non-viral gene transfer
BR112020002394A2 (pt) * 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas

Also Published As

Publication number Publication date
KR20210127935A (ko) 2021-10-25
US20220127625A1 (en) 2022-04-28
JP2024083567A (ja) 2024-06-21
AU2020221312A1 (en) 2021-10-07
CN113454232A (zh) 2021-09-28
EP3924491A1 (fr) 2021-12-22
IL285415A (en) 2021-09-30
EP3924491A4 (fr) 2022-12-14
CA3129321A1 (fr) 2020-08-20
CN113454232B (zh) 2024-10-29
SG11202106491VA (en) 2021-07-29
JP7644014B2 (ja) 2025-03-11
WO2020168222A1 (fr) 2020-08-20
JP2022520803A (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
EP3924491A4 (fr) Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée
MA51915A (fr) Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna)
MA51113A (fr) Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce)
MA50942A (fr) Protéines de liaison à l'adn modifiées
MA51842A (fr) Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion
EP3958755A4 (fr) Capteurs d'analyte préconnectés
EP3821011A4 (fr) Séquençage d'adn/arn activé par transposome (séq-arn ted)
EP3548632A4 (fr) Analyse d'adn acellulaire dans l'urine et d'autres échantillons
MA55805A (fr) Métodes de modulation de l'activité immunitaire
EP3891157A4 (fr) Composés d'aryle sulfonamide substitués par 4-amino ou 4-alcoxy ayant une activité sélective dans des canaux sodiques sensibles à la tension
EP3432918A4 (fr) Constructions d'anticorps d'adn et leur procédé d'utilisation
HUE062774T2 (hu) Módosított rAAV kapszidfehérje génterápiához
EP3705496A4 (fr) Variant d'anticorps et isoforme à activité biologique réduite
EP4401835A4 (fr) Protéines de liaison à l'antigène trem2 et leurs utilisations
DK1597282T3 (da) Antistofmolekyler, der har specificitet for human IL-1 beta
EP2279250A4 (fr) Molécules de fusion de protéines de liaison à l'adn et de domaines effecteurs conçus de façon rationnelle
EP3411056A4 (fr) Compositions pour lier des domaines de liaison à l'adn et des domaines de clivage
MA71657A (fr) Formulations de molécules protéiques comprenant de l'iduronate 2-sulfatase
EP3839070A4 (fr) Marqueur lié à la méthylation de l'adn pour diagnostiquer une tumeur, et son application
EP4081260A4 (fr) Ligase associée à une adn nucléase programmable et leurs méthodes d'utilisation
EP3835418A4 (fr) Nouvelle protéine associée aux crispr et utilisation de celle-ci
EP4058572A4 (fr) Évaluation spatiale et quantitative d'adn haute résolution
DE602006015164D1 (de) Kosmetische Verwendung von Molkeproteinmizellen
EP4442698A4 (fr) Protéine capsidique de vaa modifiée et son utilisation
IL311656A (en) Increased yield of milk protein per acre